Research & Reviews : Journal of Medical Science and Technology

ISSN: 2319-3417

Editors Overview

rrjomst maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Open Access
Special Issue

Pathophysiology of Renal erythropoietin- cells

Abstract Submission Deadline : November 30, 2023

Manuscript Submission Deadline : December 25, 2023

Special Issue Description

Chronic kidney illness (CKD) is an issue all over the world with expanding rate and prevalence. Iron deficiency, a well-known complication in CKD, is more visits in patients with lower glomerular filtration rates, particularly those with end-stage renal disease (ESRD) requiring long-term dialysis. Given that renal iron deficiency unfavorably influences the quality of life and is related to destitute results in CKD. Erythropoietin (EPO), a glycoprotein hormone, is the ace controller of erythropoiesis. Later progresses in understanding the physiology and pathophysiology of renal EPO-producing cells (REPCs) give openings to find novel medications by upgrading oxygen detecting instruments and epigenetic modification. Anemia may be a common complication and contributes to expanded horribleness and mortality in constant kidney infection (CKD) patients. Though there has been a noteworthy enhancement in of understanding the fundamental component of erythropoiesis, the treatment of renal frailty is still confined to erythropoietin (EPO)-stimulating operators. The physiology of erythropoiesis, a useful part of EPO, and the fundamental atomic and cellular premise that directs EPO generation. In CKD, plasma EPO level is out of the extent to the degree of anemia. In CKD, pericytes transdifferentiate to myofibroblasts, and hence the capacity of EPO generation diminishes, driving renal iron deficiency. Later exploratory and clinical considerations appear to the promising viability of prolyl hydroxylase inhibitors in renal iron deficiency through expanding EPO generation by stabilizing hypoxia-inducible factor (HIF).


Chronic kidney illness (CKD), End-stage renal disease (ESRD), Erythropoietin (EPO), Renal EPO-producing cells (REPCs), Epigenetic, Anemia, Hypoxia-inducible factor (HIF)

Manuscript Submission information

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

Participating journals: